L.G. and X.M. contributed equally to this work
Patients and Methods
We retrospectively reviewed patients who underwent either LPN or RAPN between 2008 and 2015. To adjust for potential baseline confounders, propensity score matching (1:1) was performed. Perioperative data, functional and oncological outcomes were reviewed. Disease-free survival, cancer-specific survival and overall survival were analysed using Kaplan-Meier survival curves with log-rank tests.
Results
In all, 197 patients underwent LPN and 96 underwent RAPN during the study period. After matching, there was no significant difference between the groups for baseline characteristics. Within the matched cohort, the LPN group was associated with significantly higher estimated blood loss (150 vs 100 mL; P < 0.001), longer renal artery clamp time (25 vs 20 min; P < 0.001), longer postoperative hospital stay (7 vs 5 days; P < 0.001), and lower rate of Margin, Ischaemia, and Complications (MIC) achievement (30.2% vs 46.9%; P = 0.018). The postoperative percentage of estimated glomerular filtration rate decline was higher in the LPN group (11.3% vs 5.5%; P = 0.018). Complication and surgical conversion outcomes were similar between LPN and RAPN. There was no significant difference in oncological outcomes between the groups.
Introduction
Partial nephrectomy (PN) is recommended for patients with T1a renal masses, as it has been shown to have comparable oncological control to radical nephrectomy but with improved renal functional outcomes [1, 2] . Due to acceptable perioperative outcomes, better functional preservation, and non-inferior cancer control [3] , PN is also recommended for T1b tumours when technically feasible. Minimally invasive PN (MIPN), namely laparoscopic PN (LPN) and robotassisted PN (RAPN), is associated with improved postoperative pain and reduced length of hospital stay whilst obtaining similar oncological control as open PN (OPN) [4, 5] . OPN has been used to manage patients with T1b renal tumours, achieving satisfactory results [6] . Meanwhile, several studies have reported the feasibility of LPN in patients with renal masses of >4 cm [7] [8] [9] . However, a laparoscopic approach may have more pronounced technical challenges than an open approach. RAPN can be considered as an evolution of LPN, with a number of published series proving its feasibility and safety for managing renal tumours of >4 cm [10] [11] [12] [13] [14] .
Based on existing data, evidence comparing LPN and RAPN in renal tumours of >4 cm is inadequate, especially with respect to the functional and intermediate oncological safety of the approaches [15] . In the present study, we report the results of a propensity score matched study comparing the perioperative, intraoperative, functional and oncological outcomes of LPN and RAPN for renal masses of >4 cm.
Patients and Methods

Study Population
From January 2008 to December 2015, 2118 patients were treated with PN for renal tumours at the Chinese PLA General Hospital. Tumour size was evaluated by preoperative CT or MRI. Patients who had bilateral or multifocal tumours, recurrent or metastatic disease were excluded. Cases belonging to surgeons' learning curves were also excluded, in order to control for this as a potential influence. After also excluding those lacking the required information, 293 consecutive cases with renal tumours of >4 cm were identified. The flow chart of patient inclusion is shown in Fig. 1 . We stratified the patients into two groups according to procedure type as follows: LPN (n = 197) and RAPN (n = 96). The LPN and RAPN surgical procedures were performed by using either a retroperitoneal or transperitoneal approach, based on the preferences of the experienced, high-volume surgeons who performed the procedure. Most of the operations were performed by three surgeons (X.M., H.L. and X.Z.), and the remainder were conducted by another two surgeons. The surgical procedures for LPN and RAPN have been previously described in detail [16, 17] . The study was approved by the Medical Ethics Committee of our hospital and informed consent was obtained from each of the patients.
Measurements and Outcomes
Baseline demographics and clinical data were abstracted from our prospectively maintained renal tumour database. Radiological features of the renal tumour were assessed by the same experienced observer (H.Z.L), according to the R.E.N.A.L. (Radius, Exophytic/Endophytic, Nearness, Anterior/Posterior, Location) nephrometry score [18] . We recorded intraoperative and postoperative complications according to the modified Clavien-Dindo classification system [19, 20] . Trifecta achievement was considered as a warm ischaemia time (WIT) of <25 min, negative surgical margins, and absence of complications, as proposed by Khalifeh et al. [21] . The components that defined Margin, Ischaemia, and Complications (MIC) achievement comprised: negative margins, WIT of <20 min, and no complications of ClavienDindo grade ≥3 [22] . For pathological variables, TNM stage was assigned according to the 2009 version, histological subtypes were based on the 2004 version of the WHO classification, and nuclear grade was based on the Fuhrman grading system. The presence of cancerous cells at the level of the inked parenchymal excision surface was considered as a positive surgical margin. Preoperative and postoperative renal function was evaluated by estimated GFR (eGFR), which was calculated using the Modification of Diet in Renal Disease study (MDRD) equation [23] . Changes in eGFR from before to 1 day and 6 months after surgery were calculated. Chronic kidney disease (CKD) staging was performed using the National Kidney Foundation Kidney Disease Outcome Quality Initiative classification. A worsening in one or more CKD categories was considered as upstaging of CKD.
After surgery, each patient was followed-up regularly until November 2016 with: a physical examination, laboratory tests, chest imaging, and abdominal ultrasonography or CT. Disease-free survival (DFS), cancer-specific survival (CSS) and overall survival (OS) were assessed from date of surgery to date of recurrence, death from renal tumour, and death from any cause at the last follow-up, respectively.
Statistical Analyses
To control for selection bias and confounding factors, a propensity score-matched analysis was performed. The propensity score was estimated using non-parsimonious Comorbidity Index (CCI), symptoms at diagnosis, history of diabetes or hypertension, solitary kidney, tumour site and size, R.E.N.A.L. nephrometry score, preoperative creatinine concentration, and eGFR. According to the estimated propensity score, patients treated with RAPN were matched 1:1 with no replacement to patients treated with LPN using the nearest-neighbour method within the matching strategy. The independent t-test or Pearson chi-squared test was used to compare covariate differences before and after matching to show that matching enhanced the balance between the two procedural groups.
All continuous data were presented as median and interquartile range (IQR) with a non-normal distribution, and as mean and standard deviation (SD) when normally distributed. For continuous data, the independent t-test or Wilcoxon rank-sum test was applied to analyse the comparisons. For categorical variables, comparisons were performed using the Pearson chi-squared or Fishers' exact test. The Kaplan-Meier method was used to estimate survival probabilities, which were compared using the logrank test. All statistical analyses were conducted with R 3.3.1 software (R, R Foundation for Statistical Computing, Vienna, Austria). Statistical significance was considered as a twosided P < 0.05.
Results
A total of 197 patients underwent LPN and 96 patients underwent RAPN during the study period. Baseline demographic and clinical features are presented in Table 1 . Before propensity score matching, compared to the RAPN cohort, patients in the LPN group had a lower median BMI (25.3 vs 26.2 kg/m 2 ; P = 0.047) and lower mean preoperative creatinine concentration (74.9 vs 80.8 lmol/L; P = 0.039). In addition, more patients in the LPN group had a posterior or 'not determined' tumour (79.2% vs 54.2%; P < 0.001). There were no statistically significant differences at baseline between the two groups for other variables.
After 1:1 matching, the balance of the key characteristics was examined, and the results showed that a good balance between the matched groups was accomplished for all matched characteristics. There was no significant difference between the groups for age, gender, BMI, ASA score, CCI score, presence of symptoms, medical history of diabetes or hypertension, solitary kidney, tumour side, tumour size, R.E.N.A.L. nephrometry score, hilar tumour, hypothermic ischaemia, preoperative creatinine concentration, and preoperative eGFR (Table 1) .
Perioperative data are shown in Table 2 . After matching, the groups had similar median operative times, at 128 vs 133 min (P = 0.234). Within the matched cohort, the LPN group was correlated with a significantly higher median estimated blood loss (150 vs 100 mL; P < 0.001), longer median renal artery clamp time (25 vs 20 min; P < 0.001), and longer median postoperative hospital stay (7 vs 5 days; P < 0.001). Outcomes of intraoperative and postoperative complications, the rate of conversion to open surgery or radical nephrectomy were comparable between the LPN and RAPN groups. The rate of MIC achievement was significantly lower in the LPN group (30.2% vs 46.9%; P = 0.018). However, the rate of Trifecta achievement was not statistically significantly different between the groups. Table 3 shows the pathological characteristics of the patients treated with LPN or RAPN. There were no significant differences between the LPN and RAPN groups for histology, pathological T-stage, Fuhrman grade, tumour necrosis, sarcomatoid features, perirenal fat invasion, and sinus fat invasion after propensity score matching (all P > 0.05). Renal functional outcomes are shown in Table 4 . After surgery, the percentage of eGFR decline was higher in the LPN group at day 1 (22.5% vs 17.1%), but was not statistically significantly different (P = 0.098). However, the difference in the percentage eGFR decline was significantly higher in the LPN group at 6 months after surgery in the matched cohort (11.3% vs 5.5%; P = 0.018). The total CKD upstaging rate was comparable for the LPN and RAPN groups.
After propensity score matching, the median follow-up periods of LPN and RAPN group were 35.0 and 20.1 months, respectively. During follow-up, disease recurrence, cancerspecific death and overall death occurred in four and four patients, one and two patients, two and two patients for the LPN and RAPN groups, respectively. Kaplan-Meier analysis showed no significant difference for DFS (P = 0.332), CSS (P = 0.197), and OS (P = 0.197; Fig. 2A-C) .
Discussion
Advances in surgical technique and improvements in the understanding of the biology of renal malignancies have resulted in the increasing application of nephron-sparing surgical procedures and minimally invasive techniques [24] . Since the advent of the robotic surgical system, the comparison of LPN and RAPN has become a 'hot' issue. Two comprehensive systematic reviews and meta-analyses have been performed by different centres, and identified that RAPN is more favourable than LPN for some perioperative [25, 26] . However, these were based on renal masses in general (and actually mostly small ones of <4 cm). For the specific group of renal tumours of >4 cm, previous studies have reported the feasibility and safety of LPN [7] [8] [9] and RAPN [10] [11] [12] [13] [14] . The advantages of RAPN over LPN for renal tumours of >4 cm still needs to be validated and specified.
The present study is a direct comparison of perioperative results, functional and oncological outcomes of LPN and RAPN for patients with renal tumours of >4 cm. In order to control for selection bias and confounding factors, the two groups were matched for key variables using propensity score analysis. Before matching, the LPN group had a lower BMI and preoperative creatinine concentration. More patients in the LPN group had a posterior or 'not determined' tumour. Table 1 shows the key variables for the two groups and shows that the matching process was successful in obtaining comparative groups.
Based on our experience, compared with LPN, RAPN has its exclusive intraoperative and postoperative benefits and advantages; namely a lower estimated blood loss, shorter renal artery clamp time and a shorter postoperative hospital stay. A recent propensity score-based study also identified that RAPN was correlated with significantly lower estimated blood loss and shorter WIT [27] . The enhanced threedimensional visualisation of the operative field, increased number of degrees of freedom, and especially the powered wrists of the robotic instruments well-suited to performing tumour resection and renal reconstruction may account for these results. Due to superior intraoperative surgical outcomes and relatively less complications, patients undergoing RAPN have a faster recovery and shorter hospitalisation time. Notably, because of obvious differences in medical insurance systems, the postoperative hospital stay in the present study was longer than the lengths of hospital stay reported in studies conducted in Western countries [10, 28] . MIC and trifecta achievement are both widely used systems for standardising the reporting of surgical outcomes. We applied both of them in the present study. Within the propensity score-matched cohort, we found that patients in RAPN group were more likely to obtain MIC achievement but trifecta achievement was similar to the LPN group. We supposed that the inconsistency of results between MIC and trifecta were mainly caused by the differing definitions of components. MIC is stricter on WIT, which may better reflect the advantage of RAPN on renal artery clamp time.
Histopathological examination revealed most of patients had malignant tumours. There were no significant differences between the groups for pathological variables, which may affect oncological outcomes. As far as renal functional outcomes, in the present study, patients undergoing RAPN had a significantly lower percentage change in postoperative eGFR. Wu et al. [27] also found that RAPN was correlated with a significantly superior preservation of postoperative renal function in propensity score-based study. A recent systematic review and meta-analysis evaluated perioperative outcomes of the two approaches and identified that RAPN had a significantly smaller change in eGFR [25] . The present results also highlighted the effect of renal artery clamp time on recovery of renal function after controlling for potential influencing factors, such as comorbidity status, R.E.N.A.L. nephrometry score and baseline renal function. Actually, Khalifeh et al. [29] proposed that WIT might have limited impact on late renal function after RAPN. Furthermore, there may be unmeasured factors favouring RAPN, such as precision in functional volume preservation and mechanical injury during suturing. After the matching process was successfully applied, the pathological variables of the LPN and RAPN groups were comparable. Based on this homogeneous population, we found no statistically significance in DFS, CSS and OS between the groups. However, the inadequate followup time precluded us from drawing any conclusions.
Due to the extensive application and marked advantages of robotic surgery, the indication for performing RAPN vs LPN seems to be of current interest. Our present study retrospectively analysed the data of patients receiving LPN or RAPN. Based on our present findings, for patients with renal tumours of >4 cm, RAPN allows for superior perioperative results and early renal functional preservation. However, according to previous publications, the direct cost of RAPN is significantly higher than LPN [30] [31] [32] . In clinical practice, the treatment decision to perform LPN or RAPN remains very complicated and must balance the cost and benefit of an individual approach. When patients' with renal tumours of >4 cm face the choice between LPN and RAPN, our present study provides robust results for patient counselling, and provides important information for clinical decision-making.
The present study was not devoid of limitations. Firstly, it is a non-randomised study with a retrospective design. Although key variables such as age, BMI, comorbidity, tumour size, R.E.N.A.L. nephrometry score, and renal function were matched, it is possible that underlying selection bias or confounding factors exist for which we did not control. Secondly, the mean follow-up was significantly shorter for the RAPN group (20.1 months) than for the LPN group (35.0 months). This discrepancy and inadequate follow-up time preclude us from drawing any conclusions. Moreover, the low rate of postoperative complications may eliminate the underlying differences between the LPN and RAPN groups. In addition, because of the developmental characteristics of the surgical techniques, most of the RAPNs were accomplished during the latter half of the study period. Nevertheless, all the procedures were performed by surgeons with extensive and high-volume experience, and cases belonging to the surgeons' learning curves were excluded.
Despite these limitations, the present study is one of the largest series to date in which the surgical and oncological outcomes of MIPN for renal masses of >4 cm are described. And we compared these outcomes of LPN and RAPN using a propensity score-matched analysis to account for potential confounding factors.
Conclusions
In summary, for patients with renal tumours of >4 cm, RAPN appears to be more favourable than LPN in terms of perioperative outcomes (i.e. estimated blood loss, renal artery clamp time and postoperative hospital stay) and early renal functional preservation. Prospective randomised studies with large samples and long-term survival follow-ups are needed to validate our present findings.
